Soligenix (SNGX) Issues Earnings Results

Share on StockTwits

Soligenix (NASDAQ:SNGX) released its quarterly earnings results on Friday. The biopharmaceutical company reported ($0.11) EPS for the quarter, meeting analysts’ consensus estimates of ($0.11), MarketWatch Earnings reports. Soligenix had a negative return on equity of 176.04% and a negative net margin of 120.14%. The company had revenue of $1.40 million during the quarter, compared to analysts’ expectations of $1.40 million.

Soligenix stock traded down $0.04 during midday trading on Friday, reaching $1.10. The company’s stock had a trading volume of 140,125 shares, compared to its average volume of 219,986. Soligenix has a 52-week low of $0.91 and a 52-week high of $3.70.

A number of equities research analysts have commented on the company. Maxim Group reiterated a “buy” rating and issued a $4.00 price target on shares of Soligenix in a research note on Thursday, September 13th. ValuEngine upgraded Soligenix from a “hold” rating to a “buy” rating in a research note on Thursday, November 1st.

In other Soligenix news, Director Mark E. Pearson purchased 170,000 shares of the firm’s stock in a transaction on Wednesday, October 17th. The stock was bought at an average cost of $1.16 per share, for a total transaction of $197,200.00. Following the completion of the purchase, the director now owns 2,500,000 shares in the company, valued at approximately $2,900,000. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Over the last quarter, insiders acquired 182,230 shares of company stock valued at $212,392. 5.03% of the stock is currently owned by company insiders.

COPYRIGHT VIOLATION WARNING: “Soligenix (SNGX) Issues Earnings Results” was originally posted by Week Herald and is the property of of Week Herald. If you are viewing this report on another domain, it was stolen and republished in violation of US & international copyright and trademark laws. The correct version of this report can be accessed at

Soligenix Company Profile

Soligenix, Inc, a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States. It operates in two segments, BioTherapeutics and Vaccines/BioDefense. The BioTherapeutics segment develops SGX301, a photodynamic therapy, which is in Phase III clinical trial to treat cutaneous T-cell lymphoma; and SGX942, an innate defense regulator technology that has completed Phase II clinical trial to treat oral mucositis in head and neck cancer.

Further Reading: Day Trading – Risk Worth the Reward?

Earnings History for Soligenix (NASDAQ:SNGX)

Receive News & Ratings for Soligenix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Soligenix and related companies with's FREE daily email newsletter.

Leave a Reply